EGFR-mutant NSCLC: emerging novel drugs

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) with EGFR mutations has seen advances, but acquired resistance remains a significant challenge.
• Developing novel agents to overcome drug resistance and block the EGFR pathway is crucial for improving patient outcomes.

Purpose of the Study:

• To review the development of novel drugs for EGFR-mutant advanced NSCLC.
• To discuss agents targeting EGFR exon 20 insertions (EGFR20ins).
• To explore the role of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in early-stage NSCLC.

Main Methods:

• Review of recent clinical trials and research findings.
• Analysis of resistance mechanisms to EGFR-TKIs.
• Investigation of novel compounds targeting specific EGFR mutations.

Main Results:

• EGFR-TKIs show promise in adjuvant or neoadjuvant therapy for early-stage NSCLC.
• Resistance mechanisms to third-generation EGFR-TKIs are EGFR-dependent or independent.
• Combining MET inhibitors with EGFR-TKIs is effective for resistance due to MET amplification/overexpression.
• Novel selective inhibitors for EGFR20ins are in Phase III studies.

Conclusions:

• Understanding resistance mechanisms to first-line and adjuvant osimertinib is essential for guiding future treatment strategies.
• Targeting specific resistance pathways, such as MET, offers therapeutic potential.
• Continued development of novel agents is necessary to address unmet needs in EGFR-mutant NSCLC.